Patients who stop GLP-1 drugs often restart or try alternatives
A large real-world study shows that patients who stop popular GLP-1–based weight-loss drugs often return to treatment or…
How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?
A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for obesity and diabetes, delivering powerful…
How GLP-1 drugs affect the body beyond weight loss and glucose control
Widely used weight-loss and diabetes drugs show clear benefits, but emerging evidence clarifies their side effects, rare risks,…
Users prioritize weight loss despite side effects
An examination of user reviews finds that people continue off-label Ozempic when it delivers results, even if side…
Improving survival in people with severe psychiatric disorders
An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing mortality gap…
Searches for “Ozempic face” surge as people look for filler-based solutions
New search data reveal that as interest in “Ozempic face” surges, people increasingly turn to nonsurgical fillers rather…
Diabetes remission possible with GLP-1 drugs, Italian study confirms
Real-world data from over 14,000 Italian adults reveal that GLP-1 receptor agonists can induce remission in type 2…
Study finds surge in the use of weight loss drugs among bariatric surgery patients
New research findings show a significant increase in the use of weight loss drugs among patients undergoing metabolic…
The role of eating styles in diabetes control
New research reveals that patients who eat in response to food cues lose more weight on GLP-1 therapy,…
GIPR signaling opens brain’s gate for GLP-1 weight-loss therapy
A new study uncovers how GIPR signaling in brain cells helps GLP-1 weight-loss drugs bypass the blood-brain barrier…
Brain’s energy control map offers blueprint for next-gen weight loss therapies
A deep dive into the brain’s command center for hunger shows how decoding its circuits could transform the…
Metformin’s blood sugar control starts in the brain, not just the liver, study finds
Scientists uncover how low-dose metformin targets brain pathways to lower blood sugar, opening fresh avenues for safer and…